Distinguished in Cystic Fibrosis

Dr. Richard Moss

Dermatology
Office
770 Welch Rd Ste 350, 
Palo Alto, CA 
Distinguished in Cystic Fibrosis
Office
770 Welch Rd Ste 350, 
Palo Alto, CA 
OverviewInsuranceLocationsClinical Research

Overview

Richard Moss is a Dermatologist in Palo Alto, California. Dr. Moss is rated as a Distinguished provider by MediFind in the treatment of Cystic Fibrosis. His top areas of expertise are Allergic Bronchopulmonary Aspergillosis, Aspergillosis, Cystic Fibrosis, and Asthma.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 42 articles and participated in 2 clinical trials in the study of Cystic Fibrosis.

Specialties
Dermatology
Licenses
Allergy & Immunology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
770 Welch Rd Ste 350, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
Enrollment Status: Completed
Publish Date: September 04, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Enrollment Status: Completed
Publish Date: February 06, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

68 Total Publications

NPCC4: Climate risk and equity-advancing knowledge toward a sustainable future | Conclusions.
NPCC4: Climate risk and equity-advancing knowledge toward a sustainable future | Conclusions.
Journal: Annals of the New York Academy of Sciences
Published: August 19, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moss's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile